Rémi Rosière
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rémi Rosière has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Karim Amighi
8 shared publicationsNathalie Wauthoz
5 shared publications- Nathalie Wauthoz
Unit of Pharmaceutics and Biopharmaceutics, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium
5 shared publications Véronique Mathieu
4 shared publications- Karim Amighi
Universite Libre de Bruxelles
3 shared publications - Thomas Mathivet
BRIC INSERM U1312, Université de Bordeaux, Pessac, France
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Elsevier in SSRN Electronic Journal
Development of safe inhalable lipid nanoparticles for the delivery of a STING agonist to lung macrophages
Pulmonary delivery represents a promising strategy for local immunomodulation in lung diseases, enabling high drug concentrations at the site of action while limiting systemic exposure. Here, we developed nebulizable mannose-functionalized lipid nanoparticles (LNPs) for the preferential delivery of the Stimulator of Interferon Genes (STING) agonist, 2'3'-cyclic Guanosine monophosphate Adenosine Monophosphate (cGAMP), to immunosuppressive subsets of lung macrophages in the context of lung cancer.,Cationic LNPs incorporating 1,2-DiOleoyl-3-TrimethylAmmonium-Propane (DOTAP) were identified as optimal for cGAMP entrapment, achieving high entrapment efficiency (around 90%). The LNPs were designed with suitable physicochemical properties (diameter <140 nm, polydispersity <0.2) and demonstrated stability during nebulization using a mesh nebulizer. Mannose functionalization enabled the LNPs to target CD206-expressing macrophages preferentially over other cells.,In vitro, cGAMP‐LNP‐Mannose significantly enhanced STING pathway activation compared with free cGAMP, particularly at low concentrations. In primary and differentiated macrophages, LNPs increased interferon beta and pro-inflammatory cytokine secretion, with data supporting a contribution from the mannose functionalization. Phenotypic analysis indicated preferential induction of a pro-inflammatory macrophage phenotype at low concentrations.,In vivo in mice, pulmonary administration of cGAMP-LNP-Mannose induced a transient, predominantly local cytokine response in the lung, modulated macrophage subsets and resulted in minimal systemic exposure. Empty LNPs exhibited minimal immunogenicity and low cytotoxicity.,Overall, these findings support the development of an inhalable, preferentially macrophage-targeting LNP platform for local immunotherapy to enhance the efficacy and safety of STING agonists and potentially other immunomodulators in the lungs.
- 30 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDevelopment of safe inhalable lipid nanoparticles for the delivery of a STING agonist to lung macrophages
Pulmonary delivery represents a promising strategy for local immunomodulation in lung diseases, enabling high drug concentrations at the site of action while limiting systemic exposure. Here, we developed nebulizable mannose-functionalized lipid nanoparticles (LNPs) for the preferential delivery of the Stimulator of Interferon Genes (STING) agonist, 2'3'-cyclic Guanosine monophosphate Adenosine Monophosphate (cGAMP), to immunosuppressive subsets of lung macrophages in the context of lung cancer.,Cationic LNPs incorporating 1,2-DiOleoyl-3-TrimethylAmmonium-Propane (DOTAP) were identified as optimal for cGAMP entrapment, achieving high entrapment efficiency (around 90%). The LNPs were designed with suitable physicochemical properties (diameter <140 nm, polydispersity <0.2) and demonstrated stability during nebulization using a mesh nebulizer. Mannose functionalization enabled the LNPs to target CD206-expressing macrophages preferentially over other cells.,In vitro, cGAMP‐LNP‐Mannose significantly enhanced STING pathway activation compared with free cGAMP, particularly at low concentrations. In primary and differentiated macrophages, LNPs increased interferon beta and pro-inflammatory cytokine secretion, with data supporting a contribution from the mannose functionalization. Phenotypic analysis indicated preferential induction of a pro-inflammatory macrophage phenotype at low concentrations.,In vivo in mice, pulmonary administration of cGAMP-LNP-Mannose induced a transient, predominantly local cytokine response in the lung, modulated macrophage subsets and resulted in minimal systemic exposure. Empty LNPs exhibited minimal immunogenicity and low cytotoxicity.,Overall, these findings support the development of an inhalable, preferentially macrophage-targeting LNP platform for local immunotherapy to enhance the efficacy and safety of STING agonists and potentially other immunomodulators in the lungs.
- 23 September 2020
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 18 (40) , 8147-8160
Deciphering the chemical instability of sphaeropsidin A under physiological conditions – degradation studies and structural elucidation of the major metabolite
The fungal metabolite sphaeropsidin A (SphA) has been recognised for its promising cytotoxicity, particularly towards apoptosis- and multidrug-resistant cancers. Owing to its intriguing activity, the development of SphA as a potential anticancer agent has been pursued. However, this endeavour is compromised since SphA exhibits poor physicochemical stability under physiological conditions. Herein, SphA's instability in biological media was explored utilizing LC-MS. Notably, the degradation tendency was found to be markedly enhanced in the presence of amino acids in the cell medium utilized. Furthermore, the study investigated the presence of degradation adducts, including the identification, isolation and structural elucidation of a major degradation metabolite, (4R)-4,4′,4′-trimethyl-3′-oxo-4-vinyl-4′,5′,6′,7′-tetrahydro-3′H-spiro[cyclohexane-1,1′-isobenzofuran]-2-ene-2-carboxylic acid. Considering the reduced cytotoxic potency of aged SphA solutions, as well as that of the isolated degradation metabolite, the reported antiproliferative activity has been attributed primarily to the parent compound (SphA) and not its degradation species. The fact that SphA continues to exhibit remarkable bioactivity, despite being susceptible to degradation, motivates future research efforts to address the challenges associated with this instability impediment.
- 23 September 2020
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 18 (40) , 8147-8160
Deciphering the chemical instability of sphaeropsidin A under physiological conditions – degradation studies and structural elucidation of the major metabolite
The fungal metabolite sphaeropsidin A (SphA) has been recognised for its promising cytotoxicity, particularly towards apoptosis- and multidrug-resistant cancers. Owing to its intriguing activity, the development of SphA as a potential anticancer agent has been pursued. However, this endeavour is compromised since SphA exhibits poor physicochemical stability under physiological conditions. Herein, SphA's instability in biological media was explored utilizing LC-MS. Notably, the degradation tendency was found to be markedly enhanced in the presence of amino acids in the cell medium utilized. Furthermore, the study investigated the presence of degradation adducts, including the identification, isolation and structural elucidation of a major degradation metabolite, (4R)-4,4′,4′-trimethyl-3′-oxo-4-vinyl-4′,5′,6′,7′-tetrahydro-3′H-spiro[cyclohexane-1,1′-isobenzofuran]-2-ene-2-carboxylic acid. Considering the reduced cytotoxic potency of aged SphA solutions, as well as that of the isolated degradation metabolite, the reported antiproliferative activity has been attributed primarily to the parent compound (SphA) and not its degradation species. The fact that SphA continues to exhibit remarkable bioactivity, despite being susceptible to degradation, motivates future research efforts to address the challenges associated with this instability impediment.
- 1 December 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 316, 250-262
Targeted PEG-poly(glutamic acid) complexes for inhalation protein delivery to the lung
- 1 December 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 316, 250-262
Targeted PEG-poly(glutamic acid) complexes for inhalation protein delivery to the lung
- Open Access
The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses
Despite new treatment modalities, including targeted therapies and checkpoint inhibitors, cytotoxic chemotherapy remains central in the care of patients with lung tumors. Use of the pulmonary route to deliver chemotherapy has been proved to be feasible and safe in phase I, Ib/IIa and II trials for lung tumors, with the administration of drug doses to the lungs without prior distribution in the organism. The severe systemic toxicities commonly observed with conventional systemic chemotherapy are consequently reduced. However, development has failed in phase II at best. This review first focuses on the causes of failure of inhaled chemotherapy. It then presents new promising technologies able to take up the current challenges. These technologies include the use of a dry powder inhaler or a smart nebulizer with advanced drug formulations such as controlled-release formulations and nanomedicine. Finally, the potential position of inhaled chemotherapy in patient care is discussed and some indications are proposed based on the literature.
Open AccessThe Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses
Despite new treatment modalities, including targeted therapies and checkpoint inhibitors, cytotoxic chemotherapy remains central in the care of patients with lung tumors. Use of the pulmonary route to deliver chemotherapy has been proved to be feasible and safe in phase I, Ib/IIa and II trials for lung tumors, with the administration of drug doses to the lungs without prior distribution in the organism. The severe systemic toxicities commonly observed with conventional systemic chemotherapy are consequently reduced. However, development has failed in phase II at best. This review first focuses on the causes of failure of inhaled chemotherapy. It then presents new promising technologies able to take up the current challenges. These technologies include the use of a dry powder inhaler or a smart nebulizer with advanced drug formulations such as controlled-release formulations and nanomedicine. Finally, the potential position of inhaled chemotherapy in patient care is discussed and some indications are proposed based on the literature.
- 1 April 2018
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 35 (4) , 378-389
La chimiothérapie inhalée – partie 2 : clinique et applications potentielles
- 1 April 2018
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 35 (4) , 378-389
La chimiothérapie inhalée – partie 2 : clinique et applications potentielles
- 1 April 2018
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 35 (4) , 357-377
La chimiothérapie inhalée – partie 1 : concept et challenges technologiques actuels
- 1 April 2018
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 35 (4) , 357-377
La chimiothérapie inhalée – partie 1 : concept et challenges technologiques actuels
- 17 January 2018
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (3) , 899-910
New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation
Inhaled chemotherapy for the treatment of lung tumours requires that drug delivery systems improve selectivity for cancer cells and tumour penetration and allow sufficient lung residence. To this end, we developed solid lipid nanoparticles (SLN) with modified surface properties. We successfully synthesized a new folate-grafted copolymer of polyethylene glycol (PEG) and chitosan, F-PEG-HTCC, with a PEG-graft ratio of 7% and a molecular weight range of 211-250 kDa. F-PEG-HTCC-coated, paclitaxel-loaded SLN were prepared with an encapsulation efficiency, mean diameter and zeta potential of about 100%, 250 nm and +32 mV, respectively. The coated SLN entered folate receptor (FR)-expressing HeLa and M109-HiFR cells in vitro, and M109 tumours in vivo after pulmonary delivery. The coated SLN significantly decreased the in vitro half maximum inhibitory concentrations of paclitaxel in M109-HiFR cells (60 vs 340 nM, respectively). We demonstrated that FR was involved in these improvements, especially in M109-HiFR cells. After pulmonary delivery in vivo, the coated SLN had a favourable pharmacokinetic profile, with pulmonary exposure to paclitaxel prolonged to up to 6 h and limited systemic distribution. Our preclinical findings therefore demonstrated the positive impact of the coated SLN on the delivery of paclitaxel by inhalation.
- 17 January 2018
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (3) , 899-910
New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation
Inhaled chemotherapy for the treatment of lung tumours requires that drug delivery systems improve selectivity for cancer cells and tumour penetration and allow sufficient lung residence. To this end, we developed solid lipid nanoparticles (SLN) with modified surface properties. We successfully synthesized a new folate-grafted copolymer of polyethylene glycol (PEG) and chitosan, F-PEG-HTCC, with a PEG-graft ratio of 7% and a molecular weight range of 211-250 kDa. F-PEG-HTCC-coated, paclitaxel-loaded SLN were prepared with an encapsulation efficiency, mean diameter and zeta potential of about 100%, 250 nm and +32 mV, respectively. The coated SLN entered folate receptor (FR)-expressing HeLa and M109-HiFR cells in vitro, and M109 tumours in vivo after pulmonary delivery. The coated SLN significantly decreased the in vitro half maximum inhibitory concentrations of paclitaxel in M109-HiFR cells (60 vs 340 nM, respectively). We demonstrated that FR was involved in these improvements, especially in M109-HiFR cells. After pulmonary delivery in vivo, the coated SLN had a favourable pharmacokinetic profile, with pulmonary exposure to paclitaxel prolonged to up to 6 h and limited systemic distribution. Our preclinical findings therefore demonstrated the positive impact of the coated SLN on the delivery of paclitaxel by inhalation.
- 1 January 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 517 (1-2) , 359-372
Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties
- 1 January 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 517 (1-2) , 359-372
Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties
- 1 December 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 515 (1-2) , 209-220
Development of controlled-release cisplatin dry powders for inhalation against lung cancers
- 1 December 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 515 (1-2) , 209-220
Development of controlled-release cisplatin dry powders for inhalation against lung cancers